| Version | Summary | Created by | Modification | Content Size | Created at | Operation |
|---|---|---|---|---|---|---|
| 1 | Yu Peng | -- | 173 | 2026-09-22 11:09:20 | | | |
| 2 | Catherine Yang | -13 word(s) | 160 | 2026-09-23 02:20:11 | | | | |
| 3 | Yu Peng | Meta information modification | 160 | 2026-09-23 05:16:14 | | |
CRISPR/Cas9 is an RNA-guided DNA-targeting system derived from the type II CRISPR adaptive immune systems of bacteria. Its core components are the Cas9 endonuclease and a guide RNA, which may consist of separate CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA) molecules or a fused single-guide RNA (sgRNA) [1]. Base pairing between the guide-derived spacer sequence and a complementary DNA protospacer directs Cas9 to a specified genomic or extrachromosomal locus. Target recognition additionally requires a nearby protospacer-adjacent motif (PAM), whose sequence is determined by the particular Cas9 ortholog; for the commonly used Streptococcus pyogenes Cas9, this motif is generally 5′-NGG-3′ [1][2]. After PAM recognition and guide–target hybridization, the HNH and RuvC nuclease domains of Cas9 cleave opposite DNA strands to generate a double-strand break [1][3]. CRISPR/Cas9 therefore denotes the guide-RNA-programmable Cas9 system itself, rather than the broader CRISPR family, which includes mechanistically distinct class 1 and class 2 CRISPR systems and non-Cas9 effector proteins [3].